Key Takeaways:
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced its Phase 3 trial for first-line metastatic melanoma failed to meet its primary endpoint, with the high-dose combination of fianlimab and cemiplimab showing a p-value of 0.0627.
"The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy," the company said in a statement.
The high-dose combination arm of the trial recorded a median progression-free survival of 11.5 months, a 5.1-month numeric improvement over the 6.4 months seen in the pembrolizumab monotherapy arm. However, the hazard ratio of 0.845 did not achieve statistical significance. No new safety signals were identified for the combination therapy.
The failure represents a setback for Regeneron's oncology pipeline in the competitive melanoma market. The company's stock has declined 9.4 percent year-to-date. Attention now turns to an ongoing Phase 3 head-to-head trial comparing the fianlimab combination against Bristol Myers Squibb's approved therapy, Opdualag.
The randomized, double-blind Phase 3 trial enrolled 1,546 patients with unresectable locally advanced or metastatic melanoma who had not received prior systemic treatment. Patients were randomized into four arms: a high-dose fianlimab combination, a low-dose combination, pembrolizumab monotherapy, and cemiplimab monotherapy.
The low-dose combination arm showed a median PFS of 9.6 months and was also not statistically significant compared to the control arm.
Detailed results from the trial are expected to be presented at an upcoming medical meeting.
The failure to meet the primary endpoint could impact Regeneron's ability to compete in the lucrative first-line melanoma treatment space. While the numeric improvement in PFS was noted, the lack of statistical significance means the result could be due to chance. The ongoing trial against Opdualag is now a critical catalyst for the program's future. Investors will be closely watching for data from that study to determine the combination's viability.
This article is for informational purposes only and does not constitute investment advice.
